Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900452 | 0.89 | ACHE (0.45) | ACHEGAAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL3895790 | 0.88 | ACHE (0.43) | ACHESLC6A3HPGDSMN1; SMN2 | |
| SCHEMBL3909908 | 0.88 | ACHE (0.44) | ACHEMAPTHPGDALDH1A1 | |
| SCHEMBL3902804 | 0.86 | ALDH1A1 (0.36) | ACHEGAAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL3905199 | 0.86 | SLC6A2 (0.41) | ACHESLC6A3MAPTHPGDSLC6A2 | |
| SCHEMBL3899791 | 0.85 | ACHE (0.39) | ACHEGAAMAPTALDH1A1 | |
| SCHEMBL3908430 | 0.85 | ACHE (0.33) | ACHEMAPT | |
| SCHEMBL4098337 | 0.84 | SLC6A3 (0.42) | SLC6A3GAAMAPTHPGDSLC6A2 | |
| SCHEMBL3897271 | 0.84 | JAK3 (0.36) | ACHEHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3908589 | 0.80 | NPC1 (0.39) | SLC6A3GAAMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0632106-B2 | Process for the production of 2,5-di(arylamino)-3,6- dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate | TOYO INK MFG CO (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20090017307-A1 | Process for the Preparation of Organic Materials | MCA TECHNOLOGIES, GMBH (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20080060554-A1 | Process for the Preparation of Organic Materials | MCA TECHNOLOGIES, GMBH (CH) | 2008-03-13 | — | — | US | disclosed |
| US-20070119345-A1 | Process for the preparation of organic materials | MCA TECHNOLOGIES, GMBH (CH) | 2007-05-31 | — | — | US | disclosed |
| EP-1725619-A1 | PROCESS FOR THE PREPARATION OF ORGANIC PIGMENTS | MCA Technologies GMBH (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085364-A1 | PROCESS FOR THE PREPARATION OF ORGANIC PIGMENTS | MCA TECHNOLOGIES GMBH (CH) | 2005-09-15 | — | — | WO | disclosed |
| EP-0632106-B1 | Process for the production of 2,5-di(arylamino)-3,6- dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate | TOYO INK MFG CO (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-5817817-A | Process for the production of 2,5-di(arylamino)-3,6-dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate | TOYO INK MANUFACTURING CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| US-5659036-A | Process for the production of 2,5-di(arylamino)-3,6-dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate | TOYO INK MANUFACTURING CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0632106-A1 | Process for the production of 2,5-di(arylamino)-3,6- dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate | TOYO INK MANUFACTURING CO., LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5093497-A | PROCESS FOR THE PREPARATION OF A SUBSTITUTED OR UNSUBSTITUTED QUINACRIDONE | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-03 | — | — | US | disclosed |
| US-4758664-A | Process for the preparation of linear quinacridones | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017307-A1 | Process for the Preparation of Organic Materials | KLK4, PDK4, GRK1 | ACHE 2362/4885SLC6A3 3377/4885GAA 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.